hypertension pulmonary arterial hypertension https://github.com/monarch-initiative/mondo/issues/5537 https://github.com/monarch-initiative/mondo/issues/5781 true Orphanet:182090 PAH with overt features of venous/capillaries involvement Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. MESH:D000081029 EFO:0001361 OMIM:615371 NCIt:C3120 A syndrome with pathological changes in the pulmonary arteries and impaired PULMONARY CIRCULATION that can be the result of PULMONARY HYPERTENSION. Ayerza syndrome is characterized by slowly developing ASTHMA; BRONCHITIS; DYSPNEA; and CYANOSIS in association with POLYCYTHEMIA. UMLS:C2973725 MedDRA:10064911 HYPERTENSION PULM GARD:7501 Syndrome, Ayerza-Arrilaga MONDO:0015924 PPH1 SCTID:11399002 MeSH:D006976 James Malone Hypertension, Pulmonary NORD:1634 SNOMEDCT:70995007 Ayerza-Arrilaga Syndrome Syndrome, Ayerza PPH PAH PHT - Pulmonary hypertension PULM HYPERTENSION Ayerza Arrilaga Syndrome pulmonary hypertension pulmonary arterial hypertension pulmonary hypertension (disorder) Pulmonary arterial hypertension (PAH) is a group of diseases characterized by mean pulmonary artery pressure >20 mmHg and elevated pulmonary arterial resistance leading to right heart failure. PAH is progressive and potentially fatal. PAH may be idiopathic and/ or familial, have overt features of venous/capillary involvement (pulmonary veno-occlusive disease, PVOD/pulmonary capillary hemangiomatosis, PCH), induced by drug or toxin (drug-or toxin-induced PAH), or associated with other diseases like congenital heart disease, connective tissue disease, HIV, schistosomiasis, portal hypertension (PAH associated with other disease). idiopathic pulmonary hypertension DOID:6432 pulmonary hypertension, primary, 1 Ayerza's Syndrome PVOD/PCH Ayerzas Syndrome Pulmonary hypertension, NOS Ayerza Syndrome